---
figid: PMC11641450__ijms-25-12804-g002
figtitle: Modulation of WNT/Beta-catenin signaling pathway by natural compounds in
  cancers
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC11641450
filename: ijms-25-12804-g002.jpg
figlink: /pmc/articles/PMC11641450/figure/F2/
number: F2
caption: Schematic representation of the modulation of WNT/β-catenin signaling pathway
  by natural compounds in cancers. The nucleus is indicated by a dashed circle, black
  arrows mark the stimulatory effect and the inhibitory effect is marked by red bar-headed
  arrows. (* an agent in the clinical trial). ALT, alantolactone, APC, adenomatous
  polyposis coli; AXIN, axis inhibition protein; BCL9, B-cell lymphoma 9; BRG1, Brahma-related
  gene-1; CBP, CREB-binding protein; CK1, casein kinase 1; DKK, Dickkopf; DVL, disheveled
  protein; EGCG, epigallocatechin-3-gallate; EVI/WLS, Evenness interrupted/Wntless;
  FZD, frizzled; GSK3β, glycogen synthase kinase 3β; LRP, lipoprotein receptor-related
  protein; Pygo, Pygopus; TCF/LEF, T-cell factor/Lymphoid enhancer factor; Ub; Ubiquitin;
  WIF1, WNT inhibitory factor 1; β-TrCP, β-transducin repeat-containing protein
papertitle: 'Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin
  Signaling in Cancer: Current State of Art and Challenges'
reftext: Anna Gajos-Michniewicz, et al. Int J Mol Sci. 2024 Dec;25(23).
year: '2024'
doi: 10.3390/ijms252312804
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: Multidisciplinary Digital Publishing Institute  (MDPI)
keywords: cancer | WNT/β-catenin signaling | natural compounds | WNT modulators |
  clinical trials
automl_pathway: 0.9328253
figid_alias: PMC11641450__F2
figtype: Figure
redirect_from: /figures/PMC11641450__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11641450__ijms-25-12804-g002.html
  '@type': Dataset
  description: Schematic representation of the modulation of WNT/β-catenin signaling
    pathway by natural compounds in cancers. The nucleus is indicated by a dashed
    circle, black arrows mark the stimulatory effect and the inhibitory effect is
    marked by red bar-headed arrows. (* an agent in the clinical trial). ALT, alantolactone,
    APC, adenomatous polyposis coli; AXIN, axis inhibition protein; BCL9, B-cell lymphoma
    9; BRG1, Brahma-related gene-1; CBP, CREB-binding protein; CK1, casein kinase
    1; DKK, Dickkopf; DVL, disheveled protein; EGCG, epigallocatechin-3-gallate; EVI/WLS,
    Evenness interrupted/Wntless; FZD, frizzled; GSK3β, glycogen synthase kinase 3β;
    LRP, lipoprotein receptor-related protein; Pygo, Pygopus; TCF/LEF, T-cell factor/Lymphoid
    enhancer factor; Ub; Ubiquitin; WIF1, WNT inhibitory factor 1; β-TrCP, β-transducin
    repeat-containing protein
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - dkk1b
  - wif1
  - lrp5
  - lrp6
  - cby1
  - gsk3ba
  - cki
  - apc
  - ctnnb1
  - wls
  - dre-mir-216a
  - bcl9
  - elk4
  - DKK1
  - WIF1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - LRP5
  - LRP6
  - RPSA
  - LRP1
  - PTPRA
  - MVP
  - GPT
  - DVL1
  - DVL1P1
  - DVL2
  - DVL3
  - GSK3B
  - CHKA
  - APC
  - PROC
  - AXIN1
  - AXIN2
  - CTNNB1
  - BTRC
  - WLS
  - HMBS
  - PORCN
  - EP300
  - CREBBP
  - EIF4E
  - OPN1LW
  - PAG1
  - PCBP4
  - MIR216A
  - BCL9
  - HNF4A
  - fisetin
  - genistein
  - EGCG
  - aloe-emodin
  - ALT
  - curcumin
  - quercetin
  - PPP
  - baicalin
  - silibinin
  - galangin
  - naringenin
  - artemisinin
  - emodin
  - lupeol
  - apigenin
  - lycopene
  - kaempferol
---
